Trials / Completed
CompletedNCT02263378
A New Supplement for the Immune Response to HPV Infection
Ellagic Acid and Annona Muricata May Modulate the Immune Response to High Risk HPV Infection. A Randomized, Controlled Trial.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University of Messina · Academic / Other
- Sex
- Female
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether a supplement in which ellagic acid plus annona muricata are combined, may modulate the immune response to high risk HPV infection. Sixty women will be enrolled in a randomized, controlled study, having a histological diagnosis of L-SIL correlated with high rish HPV types infection. Main outcome measure is the activation of onco suppressor protein by the supplement and secondary outcome is the clearance of HPV infection in the treated group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ellagic acid + annona muricata | pills |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2014-10-13
- Last updated
- 2016-05-24
Source: ClinicalTrials.gov record NCT02263378. Inclusion in this directory is not an endorsement.